Pharmacogenomics in the Clinic: Genetic Polymorphism Contributing to Venlafaxine-Associated Heart Failure

A qualitative approach to assess the opinion of physicians about the challenges and future prospects of pharmacogenomic testing implementation in clinical practice.

“…Finally, pharmaceutical companies are involved since their goal is to increase revenues and market shares. In many other studies, researchers illustrated that such resorts may lead to PGx advancement along with the reduction of PGx cost (26), (27).…”

“…In Greece, the average cost of PGx testing is 150 euros and it is considered rather affordable, while in other countries might be higher. For example, physicians in the United States underlined that most third-party vendors don't reimburse such testing and the cost is relatively high for patients (7), (27). Consequently, the pace of PGx incorporation into clinics can be slowed and varies among countries.…”

Pharmacogenetic testing in primary care could bolster depression treatment: A value proposition

“…8 However, realizing benefits from pharmacogenetic testing in real-world practice will depend on the extent to which prescribers value and use it. 9 Several implementation studies on pharmacogenetic testing have been conducted, 8,[10][11][12][13][14][15] and some specifically for psychiatric medications. [16][17][18][19][20] While prescribers have begun to use pharmacogenetic testing in routine care in different specialties, widespread adoption has lagged both across and within institutions: analysis of administrative claims for Medicare and Medicaid in one US state found that only 4.4% of Medicaid beneficiaries and 10.5% of Medicare beneficiaries who had begun a prescription of a medication included in the FDA table of drugs with pharmacogenetic testing information on the label actually received pharmacogenetic testing.…”